Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec;51(12):6095-103.
doi: 10.1167/iovs.10-5627.

Use of patient-reported outcomes in medical product development: a report from the 2009 NEI/FDA Clinical Trial Endpoints Symposium

Rohit Varma  1 , Elaine A Richman, Frederick L Ferris 3rd, Neil M Bressler
Affiliations

Use of patient-reported outcomes in medical product development: a report from the 2009 NEI/FDA Clinical Trial Endpoints Symposium

Rohit Varma et al. Invest Ophthalmol Vis Sci. 2010 Dec.
No abstract available

PubMed Disclaimer

References

    1. Csaky KS, Richman EA, Ferris FL. Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci. 2008;49:479–489 - PubMed
    1. Weinreb RN, Kaufman PL. The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci. 2009;50:1497–1505 - PubMed
    1. Hyman LG, Komaroff E, Heijl A, Bengtsson B, Leske MC. Treatment and vision-related quality of life in the early manifest glaucoma trial: Early Manifest Glaucoma Trial Group. Ophthalmology. 2005:112;1505–1513 - PubMed
    1. Janz NK, Wren PA, Lichter PR, et al. The Collaborative Initial Glaucoma Treatment Study (CIGTS): interim quality of life findings following initial medical or surgical treatment of glaucoma. Ophthalmology. 2001;108:1954–1965 - PubMed
    1. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group. Improved vision-related function after ranibizumab vs. photodynamic therapy: a randomized clinical trial. Arch Ophthalmol. 2009;127:13–21 - PubMed

Publication types